Evidence map›Paper›PMID 40275513›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

An antigen-less pro-vaccine for treating autoimmunity.

Guoxing Zheng, Thura Tun Oo, Sri Sushma Santhi Janjam, Christian Ellis, Sruthy Pallikonda Chakravarthy, Sunil Palani, Wallace Anthon, Gwendolyn Tsaras, Amanda Williams, Addysen Feng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Chaperonin in health and disease.Molecular biomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guoxing ZhengDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Thura Tun OoDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Sri Sushma Santhi JanjamDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Christian EllisDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Sruthy Pallikonda ChakravarthyDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Sunil PalaniDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Wallace AnthonDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Gwendolyn TsarasDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Amanda WilliamsDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Addysen FengDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.
Aoshuang ChenDepartment of Biomedical Sciences, University of Illinois College of Medicine Rockford, Rockford, IL, United States.

Funding

Age-related impairment in anti-HMGB1 IgM response potentiates type 2 diabetesR21AG075229 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CHEN, AOSHUANG, ZHENG, GUOXING · 2022 to 2023
$440k
Master of Science in Medical BiotechnologyNational Institute of HealthNIA NIH HHS R21 AG075229University of Illinois College of Medicine Rockford
6 · The paper itself

Abstract

We have designed the first antigen-less pro-vaccine, named 8206, for treating autoimmune diseases. Composed of dexamethasone, rapamycin, and R848 at a mass ratio of 8:20:6, 8206 is a complete tolerogenic adjuvant that acts systemically to form an active vaccine in situ with endogenous pathogenic autoantigens. This active vaccine suppresses autoimmunity by expanding antigen-specific Treg cells in affected tissues. In a mouse model of atherosclerosis, 8206 successfully targeted all three analyzed pathogenic autoantigens (ApoB, HSP60, and HMGB1) and inhibited disease progression. These findings suggest that 8206 can potentially serve as a universal treatment vaccine for autoimmune diseases by eliminating the need for exogenous immunogens, with implications for broad applications in immunotherapy.

Indexed as

Autoimmune DiseasesAutoimmunityVaccinesAdjuvants, ImmunologicAnimalsAutoantigensChaperonin 60DexamethasoneDisease Models, AnimalHumansMiceMice, Inbred C57BLSirolimusT-Lymphocytes, RegulatoryAdjuvants, ImmunologicAutoantigensChaperonin 60DexamethasoneSirolimusVaccinesautoimmunityrodentspleen and lymph nodesT cellsvaccination

Identifiers

PMID40275513
PMCPMC12442807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.